The Prevalence, Prevention, and Treatment of Cardiovascular Diseases in Twelve African Countries (2014-2019): An Analysis of the World Health Organisation STEPwise Approach to Chronic Disease Risk Factor Surveillance

Authors and affiliations

Wingston Felix Ng'ambi[1], Janne Estill[1], Fatma Aziza Merzouki[1], Cosamas Zyambo[2], David Beran[3], Olivia Keiser[1]

[1]Institute of Global Health, University of Geneva, Geneva, Switzerland

[2]University of Zambia, Department of Community Health and Family Medicine, Lusaka, Zambia

[3]Division of Tropical and Humanitarian Medicine, University of Geneva, Geneva, Switzerland

ABSTRACT

Introduction: Cardiovascular diseases (CVDs) are the most common non-communicable diseases (NCDs), responsible for more than 75% of deaths in low- and middle-income countries. We conducted this study to understand the prevalence of history of CVDs, their prevention and treatment in twelve African countries using the WHO NCDs STEPwise survey (STEPS) data.

Methods: We used secondary STEPS data from 12 African countries between 2014 and 2019. A history of heart attack, angina (chest discomfort caused by heart disease), or stroke (cerebrovascular accident or incident) was considered CVD. We fitted logistic regression models to select the predictor variables from a regression model for CVD diagnosis, CVD prevention and CVD treatment binary endpoints.

Results: Amongst 60,294 individuals, the prevalence of CVD was 5%. The CVD prevalence was higher in older individuals, females, individuals with hypertension, smokers, people with high salt intake, and in certain countries. Of the 23,630 individuals at high risk of CVD but without a history of the disease, 11% received prophylactic treatment. Amongst the 2,895 persons with CVDs, 22% received treatment or counselling for CVD: 34% receiving aspirin, 32% counselling for CVD risk factors, 11% statins, and 24% both statins and aspirin. The uptake of CVD treatment varied by hypertension status, sex, age and country.

Conclusion: The prevalence of CVD was relatively low and CVD treatment uptake was sub-optimal. Concerted efforts must be made to accelerate the diagnosis and expand treatment for CVDs in Africa if to curtail untimely deaths attributable to CVDs.

Running tittle: CVD prevalence, prevention and treatment in Africa

Key words: CVD, Cardiovascular diseases, Africa, NCD, WHO STEPS, Non-communicable diseases

INTRODUCTION

One of the aims of the United Nations Sustainable Development Goals is to reduce premature mortality from non-communicable diseases (NCDs) by a third by the year 2030 [1]. Cardiovascular diseases (CVDs), like coronary heart disease and stroke, are the most common NCDs globally responsible for an estimated 17.8 million deaths in 2017 of which more than 75% occurred in low- and middle-income countries [2]. Globally between 1990 and 2020 the age standardized DALYs for CVDs equal those of the communicable, maternal, neonatal and nutritional (CMNN) diseases combined. In 2019, CVDs were the underlying cause of 9.6 million male deaths and 8.9 million female deaths worldwide, accounting for roughly one-third of all deaths [3]. People aged 30 to 70 accounted for 6.1 million of these deaths.

While infectious diseases have historically been the primary focus of public health efforts in the region, CVDs are becoming a significant and increasing problem [4]. The prevalence of CVDs in sub-Saharan Africa (SSA) has been steadily increasing over the past few decades [4]. Despite the growing prevalence of CVDs, little is known about the trends and risk factors of the disease in SSA. Furthermore, the SSA is understudied in comparison to more resourced locations because of issues with infrastructure, CVD data availability, and healthcare systems [5]. A dearth of comprehensive and localised research that are suited to the region's particular socioeconomic and healthcare contexts is further highlighted by recent research, which emphasise efforts to shed light on the CVD epidemiology in SSA. Through region-specific analysis, these initiatives are

starting to address modifiable risk factors; nevertheless, there are still gaps in assessing the effectiveness and implementation of interventions [6]. Efforts to address this growing health concern, like improved healthcare access, awareness campaigns, and research to develop region-specific prevention and treatment strategies, are critical [7] [8].

By concentrating on SSA, the study fills a crucial gap in the literature, particularly in the context of limited healthcare resources and overlapping burdens of infectious diseases like HIV/AIDS and tuberculosis. Understanding the CVD determinants in SSA is crucial for developing effective strategies to reduce the prevalence of CVD in SSA. Furthermore, identifying the persons at highest risk of CVDs and ensuring they receive appropriate treatment can prevent more premature deaths [9] in SSA. While the WHO STEPwise approach has provided a framework for monitoring non-communicable diseases (NCDs), the potential of its data remains underutilized, especially in SSA [10]. This study provides the first multi-country analysis of CVD prevalence, prevention, and treatment in SSA using WHO STEPS data.

METHODS

Study design and setting

This is a secondary analysis of WHO STEPS data from countries with CVD data collected between 2014 and 2019 in Africa. This analysis includes data from 12 countries in Africa viz Algeria, Benin, Botswana, Eswatini, Ethiopia, Kenya, Malawi, Morocco, STP, Sudan, Uganda, Zambia. The WHO STEPS assesses risk factors for chronic non-communicable diseases and uses a multi-stage cluster sampling of households. One individual within the age range of the survey (18-69 years) was selected per household [11]. The 2014-2019 period was selected because data on CVDs were unavailable before and after this timeframe.

Variables and data management

The most recent WHO STEPS data on CVD risk factors were extracted from each country. The data were managed in R software (version 4.3.2). Box 1 provides a summary of the outcome and predictor variables, together with their classifications and computation techniques, that were taken from the most recent WHO STEPS data on CVD risk factors. We used distributions like binomial, multinomial, and Gaussian to simulate missing data based on the nature of the variables (binary, categorical with more than two groups, and continuous respectively). This approach was adopted because the Multivariate Imputation by Chained Equations (MICE) approach failed because of autocorrelation in data from five countries leading to a reduction in the sample size. In order to ascertain the uptake of treatment for prevention of CVD, all the individuals aged at least 40 years were considered to be at risk of CVD and this formed the denominator for this analysis [12].

Data analysis

Weighted percentages, counts, weighted odds ratios (OR), and the corresponding 95% confidence intervals (95%CI) were computed using the R software (version 4.3.2). The weighting variable from the WHO STEPS was based on demographic characteristics of the general population from which a sample was taken (wstep1) [13]. We conducted a set of three weighted univariable and multivariable logistic regression analyses, with quasibinomial distributions [14], of the effects of the predictor variables on: CVD prevalence in the whole dataset, CVD prevention amongst the persons at risk of CVD, and CVD treatment and counselling among those with CVD. For each of the survey-weighted multivariable logistic regression models, we first fitted a full model and then applied backward variable selection using stepAIC function contained in the MASS R CRAN package [15]. The stepAIC function performs stepwise selection to optimize the model, keeping the best subset of predictors based on the AIC criterion. We calculated the P-values for the bivariate logistic regression by comparing the model with the variable of interest and the empty model. We also calculated the P-values from adjusted models by comparing the final model with the model without the variable of interest. The level of statistical significance was set at $P<0.05$.

111

112 ## Ethical consideration

113 Individual written consent was obtained from all participants before data collection the during
114 the original WHO STEPS surveys. We requested access for secondary use of the data from the
115 World Health Organization, the funder of the WHO STEPS surveys. The WHO STEPS survey
116 datasets were downloaded from https://extranet.who.int/ncdsmicrodata/index.php/catalog/629
117 [16]. This dataset is anonymized with no identifiable information on survey respondents.

118

119 # RESULTS

120 ## Individuals included and excluded from the study

121 The distribution of individuals included in the study is shown in Figure 1. Of the 202,127
122 individuals included in the database, 60,294 (29.8%) were interviewed from 2014 onwards and
123 included information on CVD; they were therefore excluded from further analyses.

124

125 ## Characteristics of the study population

126 The characteristics of individuals included in this study are shown in Table 1. Of the 60,294
127 individuals, 44% were aged 15-29 years while 6% were aged 60 years or more. The proportions
128 of males and females were similar. More individuals were from rural areas (60%) than urban
129 areas (40%). About a third of the individuals had no education and almost half of the individuals
130 were self-employed (see Table 1). The majority of individuals were currently married. The
131 countries with highest numbers of respondents were Ethiopia (23%), Algeria (21%), and Sudan
132 (16%).

133 Nine percent of the individuals had hypertension, 6% had high cholesterol and 3% had diabetes.
134 Of the 60,294 individuals, 19,333 (33%) reported high salt uptake, 45,207 (81%) low fruit uptake,
135 and 28,905 (54%) low vegetable uptake (see Table 1). The prevalence of low level of physical
136 activity was reported as 16% while the prevalence of reported high level of physical activity was
137 65%. A total of 1,803 (3%) of the 60,294 individuals reported using alcohol in a harmful way.

138 Furthermore, 5,047 (10%) and 3348 (7%) of the 60,294 individuals reported being current and
139 previous smokers, respectively. The prevalence of reported current smoking was 10% while 6%
140 of the individuals had previously smoked or used tobacco. The prevalence of measured
141 underweight was 10% and the prevalence of overweight (i.e. BMI of at least 30 kg/m^2) was 14%.
142 The highest number of individuals were interviewed in 2015 or 2016 and the least in 2019.

143

144 **Prevalence of CVD and factors associated with CVD in twelve countries of Africa**

145 The prevalence of CVD was 5% (2895/60,294). The prevalence of CVD increased with age (see
146 Table 1). The prevalence of CVD was higher in females than males, in urban than rural areas, and
147 in individuals with hypertension, using alcohol harmfully, or being obese or overweight. Uganda
148 (9%), Malawi (7%), Botswana (6%), Algeria (6%) and Kenya (6%) had the highest, and Sudan (1%),
149 Zambia (3%), and Morocco (3%) the lowest prevalence of CVD (Table 1).

150

151 The adjusted estimates show that there was an increasing trend in CVD with age (Table 2). After
152 adjusting for sex, area of residence (urban vs rural), highest education level, marital status,
153 country of residence, having hypertension, high salt intake, physical activity level and smoking
154 status; the individuals aged 50-59 or at least 60 years were more likely to have CVD (aOR: 1.39,
155 95%CI: 1.17-1.66 and aOR: 1.67, 95%CI: 1.36-2.07, respectively) than those aged 15-29 years.
156 Males were less likely to have CVD than females (aOR: 0.65, 95%CI: 0.54-0.72, P<0.001).
157 Country-specific differences highlight the role of regional factors, with Sudan showing the lowest
158 risk and Uganda the highest as shown in Table 2. After adjusting for age, sex, area of residence,
159 highest education level, marital status, country of residence, high salt intake, physical activity
160 level and smoking status, individuals with hypertension were almost three times more likely to
161 have CVD compared to those without hypertension (aOR: 2.68, 95%CI: 2.32-3.10, P<0.001).
162 Similarly, individuals with high salt uptake were 23% more likely to have CVD than those without
163 high salt uptake (aOR: 1.23, 95%CI: 1.02-1.49, P=0.03). On the other hand, those who never
164 smoked tobacco were less likely to have CVD compared to those currently smoking (aOR: 0.69,
165 95%CI: 0.55-0.86, P<0.0001).

166

Uptake of CVD prophylaxis amongst the individuals aged at least 40 years in twelve countries of Africa

The characteristics of the 23,630 individuals who were at risk of CVD and assessed for the uptake of CVD prevention treatment and counselling are shown in Table 3. Of the 23,630 individuals: the majority (51%) were aged between 40 and 49 years, 53% were males, 56% were from rural areas, 37% had no education, 27% were from Algeria while less than 0.1% were from Morocco, 3% had diabetes, 9% had high cholesterol level, 16% had hypertension, 29% had high salt uptake, 81% had low fruit uptake, 49% had low vegetable uptake, 20% had low physical activity, 12% were current tobacco smokers, and 4% were harmful alcohol users.

Of the 23,630 persons at risk of CVD, 11% received prophylaxis or counselling. The factors associated with uptake of CVD prophylaxis are shown in Table 3. Individuals who were aged at least 50 years were more likely to get CVD prophylaxis compared to those who were aged between 40 and 49 years. Males were less likely to get CVD prophylaxis compared to females (aOR: 0.73, 95%CI: 0.58-0.932, P<0.0001), indicating a gender disparity in CVD prophylaxis uptake. Urban residents are more likely to receive prevention (aOR: 1.65, 95%CI: 1.33-2.04, P<0.0001) than their rural counterparts. Educational attainment influences uptake, with individuals having a tertiary education showing the highest uptake (see Table 3). Behavioral factors such as smoking history; with current smokers having the lower uptake compared to previous smokers (aOR: 1.17, 95% CI: 0.83-1.64) and higher uptake compared to non-smokers (aOR: 0.88, 95% CI: 0.64-1.20). Individuals with hypertension were 17 times more likely to get CVD prophylaxis compared to those without hypertension (aOR: 16.65, 95%CI:13.93-19.91, P<0.0001). There were also country variations in uptake of treatment for preventing CVDs (see Table 3). These findings suggest that targeted interventions addressing these modifiable factors could improve CVD prophylaxis uptake in Sub-Saharan Africa.

Uptake of treatment for CVDs in twelve countries of Africa

The treatment and counselling received by the respondents with CVD is shown in Figure 1. A total of 630 (22%) of the 2895 individuals with CVD received treatment or counselling. Of these

630 patients, 32% received counselling, 34% received aspirin (but no statins), 11% received statins (but no aspirin), and 24% received both statins and aspirin. The distribution of the uptake of treatment amongst the persons who had CVD is shown in Table 1. Individuals aged below 40 years had lower treatment uptake than individuals aged at least 50 years. The highest treatment uptake was observed amongst those with hypertension (53%), previous smoking history (30%), and obesity (27%) or overweight (40%). The CVD cases from Sudan had the highest (42%) and the CVD cases from Kenya the lowest treatment coverage (5%).

The factors associated with CVD treatment uptake are shown in Table 4. Age has a big impact on treatment uptake; those in the 50–59 and 60+ age groups are far more likely to get therapy than people in the 15–29 age range. In the adjusted model, sex did not significantly affect treatment uptake; males had an OR of 1.36 (0.97-1.89) compared to females, indicating that gender may not be a key driver. On the other hand, residence area is equally important; urban dwellers are more likely than their rural counterparts to receive therapy (OR 1.36, 0.97-1.90). Individuals with hypertension were 7 times more likely to take treatment for CVD than those without hypertension (aOR: 7.19, 95%CI: 5.15-9.78, P<0.001). On the other hand, individuals with low vegetable uptake were less likely to take CVD treatment than those who had high uptake of vegetables (aOR: 0.58, 95%CI: 0.54-0.83, P=0.003). Overall, these adjusted odds ratios highlight the complex interplay between individual characteristics and the likelihood of receiving CVD treatment, with older age, urban residence, and having hypertension being key factors positively influencing treatment uptake.

DISCUSSION

Our study investigated the prevalence of CVD, the uptake of CVD treatment and prophylaxis in twelve countries in Africa using a representative sample of individuals from the WHO STEPS. The overall CVD prevalence of 5% in this study was consistent with findings from a meta-analysis that found the CVD prevalence to be 7% in SSA [17]. In contrast, other regions; like USA, Europe, South and Southeast Asia and Central Asia; exhibit higher CVD prevalence [18], [19]. The low rates of CVD in Africa may be attributed to limited diagnostic capabilities for confirmation [20].

There is overwhelming evidence on the decline of cardiovascular function with age that significantly raises the risk of CVD in older adults [21] and this trend was also observed in this study. The implication is to provide the screening services to persons aged 40 years and above, as these are documented to have a high risk of CVD [2] [22] [23]. Our study is also consistent with what has been reported in other settings that more females had CVD than males [24]. Therefore, CVD prevention may be significantly increased by offering sex-specific risk factor monitoring and intervention strategies [2] [24].

The risk of CVD was shown to be three times higher among people with hypertension in SSA. This pattern is similar to studies in other locations where the relative risk of CVD among hypertensive people in North America and Europe is between two or three-fold higher [25] [26]. However, inadequate management, restricted access to therapy, and poor hypertension diagnosis result in a disproportionately higher burden for SSA [27]. This finding emphasises the critical need for better blood pressure screening, reasonably priced antihypertensive drugs, and strong primary healthcare interventions. Effectively managing hypertension could lower the risk of CVD considerably and help achieve international goals such as the Sustainable Development Goal of lowering premature mortality from non-communicable diseases by 2030.

The SSA had a lower adoption of CVD preventive therapy compared to other regions. Due to strong healthcare systems, easily accessible drugs, and effective follow-up procedures; the uptake of preventative medicines like aspirin, statins, and antihypertensives is between 50% and 60% in high-income like Australia and nations in Europe or North America [28] [29]. In order to improve preventive care and lower the rising burden of CVD in the region, this finding emphasises the urgent need for targeted interventions like bolstering primary healthcare systems, guaranteeing affordable access to necessary medications, delegating tasks to community health workers, and implementing international initiatives like WHO's HEARTS program.

253 According to our research, men were much less likely than women to obtain CVD prevention.
254 Because of maternity and reproductive health services, women often engage with healthcare
255 systems more frequently, which opens up potential for early CVD risk assessment and
256 intervention [30]. However, because of cultural norms, a perceived lack of sensitivity to chronic
257 diseases, and poorer health-seeking behavior, men may be less involved in preventive healthcare
258 [31]. This gender gap is made worse in SSA by structural issues including inadequate health care.
259 This disparity might be closed and the burden of CVD considerably decreased with gender-
260 specific programs that focus on male health behaviours, raise knowledge, and enhance access to
261 preventive treatments.

262

263 Compared to their rural counterparts, urban residents had almost double the likelihood of
264 receiving CVD prophylaxis. This gap between urban and rural areas is consistent with
265 international research showing that urban areas have more access to, infrastructure for, and
266 awareness of healthcare [32]. In SSA, access to preventative treatment is frequently restricted in
267 rural SSA due to factors like lower socioeconomic status, understaffed healthcare facilities, and
268 geographic inaccessibility [33]. Rural dwellers will continue to be disproportionately susceptible
269 to untreated cardiovascular disease risk factors in the absence of focused efforts, which will
270 increase morbidity and mortality. Increasing access to CVD prevention treatments in rural areas
271 through community-based initiatives, mobile health interventions, and decentralised healthcare
272 services must be a top priority for policymakers.

273
274 There is not much evidence on the uptake of treatment for CVD in Africa. Just 22% of people
275 with CVD in SSA received treatment, indicating a significant gap in the provision of necessary
276 care for those diagnosed of CVD. This number is significantly lower than in other continents of
277 North America, Latin America, Asia, and Europe, where between 40% and 70% of people receive
278 treatment for CVD because of their well-established healthcare systems, easy access to drugs,
279 and successful preventative initiatives [34], [35]. The glaring disparity in treatment uptake
280 highlights the persistent issues in SSA, such as the lack of adequate healthcare infrastructure, the
281 high cost of necessary pharmaceuticals, low knowledge, and a paucity of qualified medical
282 personnel, especially in underserved and rural areas [36]. This low treatment uptake has serious

ramifications because untreated CVD greatly raises the risk of negative outcomes like heart attacks, strokes, and early death. To close this gap, it is crucial to address socioeconomic barriers, integrate CVD care into basic healthcare, and provide access to cheap treatment.

In SSA, individuals with hypertension were seven times more likely than those without to receive CVD treatment, indicating that hypertension is a crucial starting point for CVD care. This pattern is consistent with research from North America and Europe, where clinical guidelines prioritise screening and treatment for hypertensive people [37] [38]. However, missed chances for early detection and management of CVD among other high-risk populations; such as those with diabetes, obesity, or tobacco use; are reflected in the poorer treatment uptake among non-hypertensive adults in SSA [34]. To close this gap and guarantee fair treatment access for all at-risk persons, thorough risk assessment instruments and integrated care pathways must be expanded in order to meet the WHO's "25 by 25" program that aims to lessen the rising burden of CVD in SSA.

This is, to our knowledge, the first multi-country study analyzing prevalence and uptake of CVD treatment in Africa using WHO STEPS. There are some analyses at country level using other sources, but such datasets, unlike WHO STEPS, are not usually nationally representative[4] [17]. The major strengths of this study were the large sample size and its representativeness. Another strength is that the study covered twelve countries and thus provides a good picture of CVD prevalence and treatment across the African continent. On the other hand, the study depended on self-reported information; therefore, some information may have been omitted intentionally or due to recall lapse. Furthermore, we were unable to estimate the extent of underestimation or overestimation of the reported CVD-related factors with heart attack and CVD treatment uptake. The study only looked at the general CVD conditions and does not provide information on the individual types of CVD. Having such information could help to choose the most suitable risk reduction interventions. Another limitation is that the WHO STEPS does not capture information on screening for CVDs although such information would better help understand the care cascade. Besides, wealth quintile is not captured in most of the WHO STEPS despite wealth index being paramount in determining equity and inequity of health outcomes. For example,

there is evidence from multiple countries across the world that wealthier individuals had higher prevalence of CVD than poorer ones [39] [40].

In conclusion; using a sizable and representative data from twelve countries, our work offers an insight into the CVD prevalence and the uptake of CVD treatment in SSA. The SSA context highlights gaps in diagnosis and treatment as compared to higher CVD prevalence in places like Europe, Asia, and North America. Hypertensive people are seven times more likely to undergo treatment, making hypertension a crucial point of entry for therapy. Important risk factors, such as smoking and excessive salt consumption, highlight the need for multi-sectoral treatments like smoking cessation programs and nutritional recommendations. Notwithstanding its advantages, such as its sizable sample size and representativeness, the study's dependence on self-reported data and its absence of details on wealth indices and particular forms of CVD point to areas that require more investigation. Achieving the Sustainable Development Goals in SSA depend on closing these disparities and putting equitable, evidence-based interventions into place.

Author contributions: WN conceptualized, conducted the analysis and prepared the manuscript; JE reviewed the analysis and the paper; OK reviewed the analysis and the paper; CZ reviewed the paper; DB reviewed the paper and provided the policy insights on the paper; FAM reviewed the analysis and the paper. All authors approved the final draft manuscript.

Acknowledgement: The authors would like to thank the World Health Organisation for granting access to use the WHO STEPS data sets for Africa.

Funding information: We received no funding to conduct this analysis.

Competing interest: We declare that there was no competing interest. The paper was prepared as part of the Doctoral Studies in Global Health at University of Geneva.

REFERENCES

[1] U. Nations, “Transforming our world: The 2030 agenda for sustainable development,” *N. Y. U. N. Dep. Econ. Soc. Aff.*, 2015.

[2] S. Kaptoge *et al.*, “World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions,” *Lancet Glob. Health*, vol. 7, no. 10, pp. e1332–e1345, Oct. 2019, doi: 10.1016/S2214-109X(19)30318-3.

[3] G. A. Roth, G. A. Mensah, and V. Fuster, “The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action,” *J. Am. Coll. Cardiol.*, vol. 76, no. 25, pp. 2980–2981, Dec. 2020, doi: 10.1016/j.jacc.2020.11.021.

[4] N. W. Minja *et al.*, “Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward.,” *Front. Cardiovasc. Med.*, vol. 9, p. 1008335, 2022, doi: 10.3389/fcvm.2022.1008335.

[5] J. Sun, Y. Qiao, M. Zhao, C. G. Magnussen, and B. Xi, “Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of Global Burden of Disease Study 2019,” *BMC Med.*, vol. 21, no. 1, p. 222, Jun. 2023, doi: 10.1186/s12916-023-02925-4.

[6] Vaduganathan Muthiah, Mensah George A., Turco Justine Varieur, Fuster Valentin, and Roth Gregory A., “The Global Burden of Cardiovascular Diseases and Risk,” *J. Am. Coll. Cardiol.*, vol. 80, no. 25, pp. 2361–2371, Dec. 2022, doi: 10.1016/j.jacc.2022.11.005.

[7] L. J. Jack, “Advancing Health Equity, Eliminating Health Disparities, and Improving Population Health,” *Prev. Chronic. Dis.*, vol. 18, p. E79, 2021, doi: 10.5888/pcd18.210264.

[8] N. Pronk, D. V. Kleinman, S. F. Goekler, E. Ochiai, C. Blakey, and K. H. Brewer, “Promoting Health and Well-being in Healthy People 2030.,” *J. Public Health Manag. Pract. JPHMP*, vol. 27, no. Suppl 6, pp. S242–S248, Dec. 2021, doi: 10.1097/PHH.0000000000001254.

[9] J. Stewart, G. Manmathan, and P. Wilkinson, “Primary prevention of cardiovascular disease: A review of contemporary guidance and literature.,” *JRSM Cardiovasc. Dis.*, vol. 6, p. 2048004016687211, Dec. 2017, doi: 10.1177/2048004016687211.

[10] “World Health Organization (WHO). STEPS: A Framework for Surveillance. The WHO STEPwise Approach to Surveillance of Noncommunicable Diseases (STEPS). Geneva, Switzerland: WHO; 2003.”

[11] WHO, “STEPwise approach to NCD risk factor surveillance (STEPS).” 2022. Accessed: Jul. 20, 2022. [Online]. Available: https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps

[12] K. Kim, “Risk stratification of cardiovascular disease according to age groups in new prevention guidelines: a review,” *J. Lipid Atheroscler.*, vol. 12, no. 2, p. 96, 2023.

[13] WHO, “The WHO STEPwise approach to noncommunicable disease risk factor surveillance.” WHO, Geneva, Switzerland, Jan. 26, 2017. Accessed: Apr. 20, 2024. [Online]. Available: https://www.who.int/docs/default-source/ncds/ncd-surveillance/steps/steps-manual.pdf?sfvrsn=c281673d_5

[14] “Simmonds, M. and Higgins, J. P. T. (2016). A general framework for the use of logistic regression models in meta-analysis. Statistical Methods in Medical Research, 25(6), 2858-2877. https://doi.org/10.1177/0962280214534409.”

[15] “Ripley, B. and Venables, B. (2009). Mass: support functions and datasets for venables and ripley’s mass. CRAN: Contributed Packages. https://doi.org/10.32614/cran.package.mass.”

[16] E. Osei *et al.*, “Prevalence and predictors of selected risk factors of non-communicable diseases in Ghana: evidence from a sub-national survey,” *J. Glob. Health Sci.*, vol. 3, no. 2, pp. 1–14, 2021, doi: 10.35500/jghs.2021.3.e13.

[17] V. N. Agbor, M. Essouma, N. A. Ntusi, U. F. Nyaga, J. J. Bigna, and J. J. Noubiap, “Heart failure in sub-Saharan Africa: a contemporaneous systematic review and meta-analysis,” *Int. J. Cardiol.*, vol. 257, pp. 207–215, 2018.

[18] G. A. Mensah, V. Fuster, C. J. L. Murray, and G. A. Roth, “Global Burden of Cardiovascular Diseases and Risks, 1990-2022.,” *J. Am. Coll. Cardiol.*, vol. 82, no. 25, pp. 2350–2473, Dec. 2023, doi: 10.1016/j.jacc.2023.11.007.

[19] C. W. Tsao *et al.*, “Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association,” *Circulation*, vol. 145, no. 8, pp. e153–e639, Feb. 2022, doi: 10.1161/CIR.0000000000001052.

[20] N. W. Minja *et al.*, “Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward.,” *Front. Cardiovasc. Med.*, vol. 9, p. 1008335, 2022, doi: 10.3389/fcvm.2022.1008335.

[21] B. J. North and D. A. Sinclair, “The Intersection Between Aging and Cardiovascular Disease,” *Circ. Res.*, vol. 110, no. 8, pp. 1097–1108, Apr. 2012, doi: 10.1161/CIRCRESAHA.111.246876.

[22] Cho Leslie *et al.*, “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women,” *J. Am. Coll. Cardiol.*, vol. 75, no. 20, pp. 2602–2618, May 2020, doi: 10.1016/j.jacc.2020.03.060.

[23] *Cardiovascular disease: risk assessment and reduction, including lipid modification. London: National Institute for Health and Care Excellence (NICE); 2023 Dec 14. (NICE Clinical Guidelines, No. 238.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK602380/*.

[24] A. K. McClain, P. P. Monteleone, and J. Zoldan, “Sex in cardiovascular disease: Why this biological variable should be considered in in vitro models,” *Sci. Adv.*, vol. 10, no. 19, p. eadn3510, doi: 10.1126/sciadv.adn3510.

[25] K. T. Mills *et al.*, “Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.,” *Circulation*, vol. 134, no. 6, pp. 441–450, Aug. 2016, doi: 10.1161/CIRCULATIONAHA.115.018912.

[26] “Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants.,” *Lancet Lond. Engl.*, vol. 389, no. 10064, pp. 37–55, Jan. 2017, doi: 10.1016/S0140-6736(16)31919-5.

[27] S. F. Mohamed, O. A. Uthman, M. K. Mutua, G. Asiki, M. S. Abba, and P. Gill, “Prevalence of uncontrolled hypertension in people with comorbidities in sub-Saharan Africa: a systematic review and meta-analysis.,” *BMJ Open*, vol. 11, no. 12, p. e045880, Dec. 2021, doi: 10.1136/bmjopen-2020-045880.

[28] G. A. Roth *et al.*, “Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.,” *J. Am. Coll. Cardiol.*, vol. 70, no. 1, pp. 1–25, Jul. 2017, doi: 10.1016/j.jacc.2017.04.052.

[29] B. Zhou *et al.*, “Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants,” *The Lancet*, vol. 398, no. 10304, pp. 957–980, Sep. 2021, doi: 10.1016/S0140-6736(21)01330-1.

[30] H.-L. Kim, “Differences in Risk Factors for Coronary Atherosclerosis According to Sex.,” *J. Lipid Atheroscler.*, vol. 13, no. 2, pp. 97–110, May 2024, doi: 10.12997/jla.2024.13.2.97.

[31] A. Peerson and M. Saunders, “Men’s health literacy: advancing evidence and priorities,” *Crit. Public Health*, vol. 19, no. 3–4, pp. 441–456, Sep. 2009, doi: 10.1080/09581590902906229.

[32] R. Gupta, “Convergence in urban-rural prevalence of hypertension in India.,” *J. Hum. Hypertens.*, vol. 30, no. 2, pp. 79–82, Feb. 2016, doi: 10.1038/jhh.2015.48.

[33] S. Dunachie and P. Chamnan, “The double burden of diabetes and global infection in low and middle-income countries.,” *Trans. R. Soc. Trop. Med. Hyg.*, vol. 113, no. 2, pp. 56–64, Feb. 2019, doi: 10.1093/trstmh/try124.

[34] *Rao H. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Indian Heart J. 2012 Jan;64(1):113. doi: 10.1016/S0019-4832(12)60034-0. PMCID: PMC3861210.*

[35] S. S. Virani *et al.*, “Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.,” *Circulation*, vol. 143, no. 8, pp. e254–e743, Feb. 2021, doi: 10.1161/CIR.0000000000000950.

[36] R. Khatib *et al.*, “Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.,” *Lancet Lond. Engl.*, vol. 387, no. 10013, pp. 61–69, Jan. 2016, doi: 10.1016/S0140-6736(15)00469-9.

[37] K. Kotseva *et al.*, “Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.,” *Eur. J. Prev. Cardiol.*, vol. 23, no. 18, pp. 2007–2018, Dec. 2016, doi: 10.1177/2047487316667784.

[38] K. T. Mills *et al.*, “Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.,” *Circulation*, vol. 134, no. 6, pp. 441–450, Aug. 2016, doi: 10.1161/CIRCULATIONAHA.115.018912.

[39] C. Brindley, T. Van Ourti, J. Capuno, A. Kraft, J. Kudymowa, and O. O’Donnell, “Risk factor contributions to socioeconomic inequality in cardiovascular risk in the Philippines: a cross-sectional study of nationally representative survey data,” *BMC Public Health*, vol. 23, no. 1, p. 689, Apr. 2023, doi: 10.1186/s12889-023-15517-x.

[40] A. Rosengren *et al.*, “Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study,” *Lancet Glob. Health*, vol. 7, no. 6, pp. e748–e760, Jun. 2019, doi: 10.1016/S2214-109X(19)30045-2.

Box 1: Outcome and predictor variables included in the analysis

Variable	**Categories**	**Calculation**
Outcome Variables		
History of CVD	Yes, No	Response to: “Have you ever had a heart attack, angina, or stroke?” (Yes = CVD present, No = CVD absent)
Taking aspirin regularly	Yes, No	Response to: “Are you currently taking aspirin regularly to prevent or treat heart disease?”
Taking statins regularly	Yes, No	Response to: “Are you currently taking statins regularly to prevent or treat heart disease?”
Lifestyle counseling	Yes, No	Response to whether the participant has received lifestyle counseling for CVD prevention
Predictor Variables		
Harmful alcohol use	Yes, No	Defined as daily drinking and having at least 4 (males) or 3 (females)

		drinking occasions in the last 30 days (AUDIT-C)
Low vegetable consumption	<5 times/week, ≥5 times/week	Response to: "In a typical week, on how many days do you eat vegetables?" (<5 times/week = low consumption)
Low fruit consumption	<5 times/week, ≥5 times/week	Response to: "In a typical week, on how many days do you eat fruit?" (<5 times/week = low consumption)
Physical inactivity	<150 min/week, ≥150 min/week	Less than 150 minutes of moderate-intensity physical activity per week
High salt intake	Yes, No	Response to: "How often do you add salt or a salty sauce to your food right before you eat it or as you are eating it?" (Regularly/often eating high-salt processed food = high intake)
History of raised blood pressure	SBP ≥160 mmHg and/or DBP ≥100 mmHg, or on medication	Systolic BP ≥160 mmHg and/or Diastolic BP ≥100 mmHg or currently on antihypertensive medication
History of raised blood glucose	Blood glucose ≥6.1 mmol/L	Capillary whole blood glucose measurement of ≥6.1 mmol/L
Smoking history	Current smoker, Previous smoker, Never smoked	Self-reported smoking status (Current, Previous, Never)
Body mass index (BMI)	<18.5, 18.5-24.0, 25.0-29.0, 30.0+ kg/m² (excluding pregnant women)	BMI = weight (kg) / height (m²)
Sex	Male, Female	Self-reported biological sex
Age (years)	15-29, 30-39, 40-49, 50-59, 60+	Calculated from date of birth (completed calendar years)
Education	None, Primary, Secondary, Tertiary	Self-reported highest level of education completed
Occupation	Government employee, Non-government employee, Self-employed, Retired/Not working (e.g., students, unemployed)	Self-reported employment status
Type of residence	Rural, Urban	Categorized based on place of residence
Country	Malawi, Kenya, Zambia, etc	Recorded based on WHO STEPS country data

Marital status	Never married, Married, Previously married	Self-reported marital status

465

466 Table 1: Characteristics of the study population, the CVD cases, and treatment uptake in twelve African
467 countries between 2014 and 2019. The percentages for the study population are column percentages; for
468 CVD cases and patients who received CVD treatment, the percentages are row percentages with the
469 denominator being the whole study population within the respective category for CVD cases; and CVD
470 cases within the respective category for patients who received CVD treatment.

Characteristics	Study population[a]		CVD cases[b]		Received CVD treatment[c]	
	N	%	n	%	n	%
Total	60294	100.0	2895	4.6	630	18.5
Age group						
15-29	19351	44.1	748	3.6	71	9.2
30-39	15853	23.0	687	4.6	81	7.9
40-49	11563	16.6	553	5.1	109	19.4
50-59	7929	10.3	484	6.2	173	36.5
60+	5598	6.0	423	8.4	196	45.4
Sex						
Female	37010	48.8	1961	5.6	430	18.2
Male	23284	51.2	934	3.7	200	19.0
Area of residence						
Rural	33718	59.7	1590	4.3	258	13.1
Urban	26576	40.3	1305	5.1	372	25.2
Highest level of education						
None	20174	29.0	947	4.4	229	20.3
Primary	19647	35.0	1057	5.5	220	17.1
Secondary	14915	25.7	655	4.0	116	16.7
Tertiary	5558	10.2	236	3.8	65	24.4
Occupation						
Government employee	4413	7.8	203	3.9	59	23.3
Non-Govt employee	4622	8.7	210	3.7	45	21.6
Non-paid/Retired	25400	36.2	1180	5.2	289	20.6
Self-employed	25859	47.3	1302	4.5	237	15.5
Marital status						
Currently married	39949	68.5	2060	4.9	474	19.9
Formerly married	4019	5.4	243	6.8	49	12.8
Never married	16326	26.1	592	3.4	107	15.6
Country						
Algeria	6955	21.1	415	5.6	178	38.0
Benin	5115	1.8	293	4.7	47	18.7
Botswana	3888	0.6	210	5.8	45	16.9
Eswatini	3026	0.2	131	4.9	26	23.1
Ethiopia	9241	23.4	337	3.5	51	9.7
Kenya	4477	14.1	296	5.6	18	5.1

Malawi	4186	6.4	312	6.5	64	13.9
Morocco	4991	0.0	163	3.1	59	31.3
STP	2418	0.2	90	3.4	26	27.9
Sudan	7722	16.2	117	1.2	54	42.4
Uganda	3973	10.0	371	8.9	38	10.2
Zambia	4302	6.1	160	3.0	24	16.4
Having diabetes						
No	58800	97.4	2814	4.6	608	18.4
Yes	1494	2.6	81	4.1	22	23.6
Having high cholesterol level						
Yes	5926	6.2	279	5.0	79	18.6
No	54368	93.8	2616	4.6	551	18.5
Having hypertension						
No	52772	91.5	2100	3.9	218	9.1
Yes	7522	8.5	795	11.8	412	52.6
High salt intake						
No	40961	66.8	2005	4.7	467	21.0
Yes	19333	33.2	890	4.5	163	13.1
Low fruit uptake						
No	14037	18.7	719	4.9	188	24.0
Yes	46257	81.3	2176	4.5	442	17.1
Low vegetable uptake						
No	31130	46.3	1511	4.9	384	24.5
Yes	29164	53.7	1384	4.4	246	12.7
Physical activity level						
Low Level	12325	16.4	562	4.6	199	34.5
Moderate level	12725	19.7	565	4.4	153	23.9
High level	35244	63.9	1768	4.7	278	12.9
Smoking history						
Current	5047	10.2	258	5.2	45	16.4
Never	51899	83.2	2425	4.4	518	17.6
Previous	3348	6.7	212	5.8	67	29.6
Harmful alcohol use						
No	58491	97.1	2775	4.6	615	18.7
Yes	1803	2.9	120	5.4	15	14.0
BMI						
<18.5	7899	15.5	331	3.5	50	12.9
18.5-24	29966	53.0	1426	4.7	199	10.8
25-29	12417	17.5	617	5.2	180	27.4
30+	10012	14.0	521	4.9	201	38.8
Survey year						
2014	10887	10.8	712	8.7	109	10.6
2015	18833	39.2	926	4.3	116	8.0
2016	14677	37.3	532	3.7	232	38.6
2017	13479	12.5	635	4.8	147	14.7
2019	2418	0.2	90	3.4	26	27.9

471 a is the denominator for b when calculating the prevalence of CVD cases

472 b is the denominator for c when calculating uptake of CVD treatment amongst the CVD cases

473

474 Table 2: Factors associated with prevalence for cardiovascular diseases in twelve African countries

475 between 2014 and 2019

476

Characteristics	Crude		Adjusted	
	OR (95%CI)	P-value[a]	OR (95%CI)	P-value[b]
Age group		<0.0001		<0.0001
15-29	1.00		1.00	
30-39	1.30 (1.11-1.51)		1.15 (0.98-1.36)	
40-49	1.47 (1.23-1.76)		1.25 (1.03-1.51)	
50-59	1.80 (1.51-2.13)		1.39 (1.17-1.66)	
60+	2.47 (2.04-3.00)		1.67 (1.36-2.07)	
Sex		<0.0001		<0.0001
Female	1.00		1.00	
Male	0.64 (0.57-0.72)		0.65 (0.54-0.72)	
Area of residence		0.05		0.17
Rural	1.00		1.00	
Urban	1.20 (1.00-1.44)		1.17 (0.97-1.38)	
Highest level of education		0.0001		0.0001
None	1.00		1.00	
Primary	1.26 (1.05-1.50)		1.16 (0.97-1.38)	
Secondary	0.90 (0.74-1.09)		0.91 (0.74-1.11)	
Tertiary	0.85 (0.67-1.07)		0.87 (0.68-1.12)	
Occupation		0.01		
Government employee	1.00			
Non-Govt employee	0.97 (0.70-1.33)			
Non-paid/Retired	1.36 (1.07-1.72)			
Self-employed	1.17 (0.91-1.50)			
Marital status		<0.0001		
Currently married	1.00			
Formerly married	1.42 (1.11-1.83)			
Never married	0.68 (0.58-0.80)			
Country		<0.0001		<0.0001
Algeria	1.00		1.00	
Benin	0.84 (0.60-1.18)		1.11 (0.77-1.58)	
Botswana	1.05 (0.79-1.41)		0.91 (0.65-1.28)	
Eswatini	0.87 (0.63-1.21)		0.93 (0.66-1.30)	
Ethiopia	0.62 (0.47-0.84)		0.81 (0.58-1.14)	
Kenya	1.01 (0.73-1.39)		1.09 (0.80-1.50)	
Malawi	1.18 (0.89-1.57)		1.12 (0.82-1.52)	

Morocco	0.54 (0.42-0.69)		0.59 (0.46-0.76)	
STP	0.59 (0.41-0.85)		0.54 (0.37-0.79)	
Sudan	0.20 (0.15-0.28)		0.25 (0.18-0.35)	
Uganda	1.66 (1.29-2.14)		2.04 (1.55-2.69)	
Zambia	0.53 (0.40-0.71)		0.57 (0.43-0.77)	
Having diabetes		0.44		
No	1.00			
Yes	0.87 (0.62-1.24)			
Having high cholesterol level		0.47		
Yes	1.00			
No	0.91 (0.71-1.16)			
Having hypertension		<0.0001		<0.0001
No	1.00		1.00	
Yes	3.26 (2.84-3.75)		2.68 (2.32-3.10)	
High salt intake		0.57		0.41
No	1.00		1.00	
Yes	0.95 (0.79-1.14)		1.23 (1.02-1.49)	
Low fruit uptake		0.24		0.76
No	1.00		1.00	
Yes	0.92 (0.80-1.06)		1.09 (0.94-1.27)	
Low vegetable uptake		0.12		
No	1.00			
Yes	0.88 (0.76-1.03)			
Physical activity level		0.67		0.002
Low Level	1.00		1.00	
Moderate level	0.96 (0.80-1.16)		1.07 (0.88-1.29)	
High level	1.03 (0.87-1.23)		1.14 (0.96-1.36)	
Smoking history		0.02		<0.0001
Current	1.00		1.00	
Never	0.84 (0.69-1.03)		0.69 (0.55-0.86)	
Previous	1.12 (0.88-1.46)		0.94 (0.71-1.22)	
Harmful alcohol use		0.31		
No	1.00			
Yes	1.18 (0.86-1.61)			
BMI		0.001		
<18.5	1.00			
18.5-24	1.36 (1.13-1.63)			
25-29	1.52 (1.23-1.87)			
30+	1.44 (1.14-1.80)			

[a]P-value from analysis of variance test for an empty model vs a model with a single variable

[b]P-value from analysis of variance where the final model was compared to the model without the corresponding variable

481 Table 3: Characteristics of persons who were at risk of cardiovascular diseases, the uptake of prevention of CVD and the factors associated with the
482 uptake of prevention services for CVD in Africa between 2014 and 2019

483

Characteristics	Total		Received prevention		Crude		Adjusted	
	n	%	n	%	OR (95%CI)	P-value	OR (95%CI)	P-value
Total	23630	100.0	2665	11.3				
Age group						<0.0001		<0.0001
40-49	11010	51.0	711	5.8	1.00		1.00	
50-59	7445	31.2	997	11.6	2.11 (1.79-2.49)		1.80 (1.47-2.20)	
60+	5175	17.8	957	16.6	3.21 (2.69-3.83)		2.40 (1.95-2.96)	
Sex						<0.0001		<0.0001
Female	13763	46.6	1893	12.7	1.00		1.00	
Male	9867	53.4	772	6.8	0.50 (0.44-0.58)		0.73 (0.58-0.92)	
Area of residence						<0.0001		<0.0001
Rural	12560	55.9	878	5.1	1.00		1.00	
Urban	11070	44.1	1787	15.2	3.32 (2.77-3.98)		1.65 (1.33-2.04)	
Highest level of education						<0.0001		<0.0001
None	10123	36.5	996	6.8	1.00		1.00	
Primary	7526	34.8	825	9.5	1.45 (1.22-1.72)		1.04 (0.84-1.30)	
Secondary	4281	20.6	554	11.7	1.84 (1.50-2.25)		1.23 (0.95-1.59)	
Tertiary	1700	8.1	290	16.7	2.77 (2.20-3.49)		1.24 (0.91-1.69)	
Occupation						<0.0001		
Government employee	1974	10.2	289	13.0	1.00			
Non-Govt employee	1748	8.6	160	8.8	0.65 (0.46-0.90)			
Non-paid/Retired	9905	36.3	1450	12.9	0.99 (0.79-1.25)			
Self-employed	10003	44.9	766	6.2	0.44 (0.35-0.56)			
Marital status						0.79		0.01
Currently married	18714	85.9	2032	9.6	1.00		1.00	
Formerly married	2296	7.8	291	9.8	1.03 (0.80-1.33)		1.37 (0.98-1.92)	

Never married	2620	6.3	342	8.9	0.92 (0.73-1.17)		0.70 (0.53-0.93)	
Country						<0.0001		<0.0001
Algeria	3375	27.1	725	20.1	1.00		1.00	
Benin	1894	1.7	66	3.8	0.16 (0.11-0.23)		0.28 (0.19-0.40)	
Botswana	1408	0.5	336	21.7	1.10 (0.88-1.38)		1.51 (1.09-2.09)	
Eswatini	1189	0.2	191	15.6	0.74 (0.59-0.93)		0.47 (0.36-0.63)	
Ethiopia	3105	20.5	133	2.7	0.11 (0.08-0.15)		0.42 (0.27-0.65)	
Kenya	1626	13.0	80	4.9	0.21 (0.14-0.31)		0.22 (0.14-0.35)	
Malawi	1518	5.8	77	4.5	0.19 (0.13-0.28)		0.34 (0.22-0.52)	
Morocco	2680	0.0	426	14.2	0.66 (0.57-0.77)		0.68 (0.55-0.84)	
STP	897	0.2	115	13.8	0.64 (0.49-0.83)		0.52 (0.36-0.75)	
Sudan	3219	16.6	415	11.8	0.54 (0.43-0.66)		0.98 (0.76-1.25)	
Uganda	1184	8.9	41	2.9	0.12 (0.07-0.20)		0.20 (0.12-0.36)	
Zambia	1535	5.5	60	4.0	0.17 (0.11-0.25)		0.15 (0.10-0.23)	
Having diabetes								
No	23012	97.0	2561	9.4	1.00			
Yes	618	3.0	104	14.6	1.65 (1.21-2.24)	0.003		
Having high cholesterol level						0.02		
Yes	2899	8.7	433	11.7	1.00			
No	20731	91.3	2232	9.3	0.78 (0.64-0.95)			
Having hypertension						<0.0001		<0.0001
No	19015	84.3	618	3.4	1.00		1.00	
Yes	4615	15.7	2047	42.6	21.17 (17.99-24.91)		16.65 (13.93-19.91)	
High salt intake						<0.0001		<0.0001
No	16856	70.7	2000	11.4	1.00		1.00	
Yes	6774	29.3	665	5.0	0.41 (0.34-0.49)		0.60 (0.48-0.75)	
Low fruit uptake						<0.0001		0.01
No	5693	19.4	843	14.4	1.00		1.00	
Yes	17937	80.6	1822	8.4	0.54 (0.47-0.63)		0.80 (0.66-0.98)	
Low vegetable uptake						<0.0001		0.004
No	13099	50.9	1776	12.7	1.00		1.00	
Yes	10531	49.1	889	6.3	0.46 (0.39-0.54)		0.78 (0.63-0.96)	

Physical activity level						<0.0001		<0.0001
Low Level	5588	20.2	928	16.2	1.00		1.00	
Moderate level	5013	20.3	732	13.3	0.79 (0.67-0.93)		1.13 (0.91-1.39)	
High level	13029	59.5	1005	6.0	0.33 (0.28-0.39)		0.78 (0.63-0.96)	
Smoking history						<0.0001		0.008
Current	2342	11.7	158	6.4	1.00		1.00	
Never	19338	77.2	2252	9.6	1.57 (1.24-1.98)		0.88 (0.64-1.20)	
Previous	1950	11.1	255	12.2	2.05 (1.52-2.75)		1.17 (0.83-1.64)	
Harmful alcohol use						<0.0001		0.001
No	22800	96.2	2633	9.8	1.00		1.00	
Yes	830	3.8	32	2.5	0.24 (0.12-0.48)		0.66 (0.28-1.49)	
BMI						<0.0001		<0.0001
<18.5	2990	14.9	195	5.7	1.00		1.00	
18.5-24	10199	46.1	637	5.1	0.88 (0.69-1.13)		0.92 (0.70-1.21)	
25-29	5612	21.4	808	13.9	2.65 (2.07-3.39)		1.28 (0.96-1.72)	
30+	4829	17.6	1025	19.2	3.90 (3.04-4.99)		1.36 (1.01-1.82)	
Survey year						<0.0001		
2014	3781	9.6	568	4.1	1.00			
2015	6625	35.2	279	3.6	0.85 (0.56-1.30)			
2016	6594	43.6	1140	16.9	4.72 (3.34-6.68)			
2017	5733	11.4	563	4.3	1.04 (0.67-1.61)			
2019	897	0.2	115	13.8	3.72 (2.48-5.59)			

[a]P-value from analysis of variance test for an empty model vs a model with a single variable

[b]P-value from analysis of variance where the final model was compared to the model without the corresponding variable

488 Table 4: Factors associated with uptake of treatment for cardiovascular diseases in twelve African countries between 2014 and 2019

Characteristics	Crude		Adjusted	
	OR (95%CI)	P-value	OR (95%CI)	P-value
Age group		<0.0001		<0.0001
15-29	1.00		1.00	
30-39	0.85 (0.52-1.38)		0.56 (0.32-0.98)	
40-49	2.39 (1.51-3.77)		1.15 (0.67-1.96)	
50-59	5.70 (3.67-8.86)		2.31 (1.39-3.84)	
60+	8.26 (5.24-13.00)		2.90 (1.75-4.82)	
Sex		0.67		0.83
Female	1.00		1.00	
Male	1.06 (0.81-1.38)		1.36 (0.97-1.89)	
Area of residence		<0.0001		<0.0001
Rural	1.00		1.00	
Urban	2.24 (1.72-2.90)		1.36 (0.97-1.90)	
Highest level of education		0.15		
None	1.00			
Primary	0.81 (0.60-1.10)			
Secondary	0.79 (0.55-1.15)			
Tertiary	1.27 (0.81-1.99)			
Occupation		0.04		
Government employee	1.00			
Non-Govt employee	0.91 (0.47-1.75)			
Non-paid/Retired	0.86 (0.53-1.38)			
Self-employed	0.61 (0.37-0.98)			
Marital status		0.05		
Currently married	1.00			
Formerly married	0.59 (0.36-0.98)			
Never married	0.74 (0.51-1.08)			
Country		<0.0001		<0.0001

Algeria	1.00		1.00	
Benin	0.38 (0.24-0.60)		0.84 (0.42-1.65)	
Botswana	0.33 (0.17-0.66)		0.44 (0.16-1.20)	
Eswatini	0.49 (0.25-0.95)		0.49 (0.25-1.00)	
Ethiopia	0.18 (0.11-0.28)		0.63 (0.35-1.12)	
Kenya	0.09 (0.05-0.18)		0.14 (0.07-0.30)	
Malawi	0.26 (0.17-0.41)		0.39 (0.22-0.69)	
Morocco	0.74 (0.50-1.11)		0.65 (0.38-1.11)	
STP	0.63 (0.34-1.16)		0.43 (0.19-0.99)	
Sudan	1.20 (0.72-2.00)		1.56 (0.89-2.75)	
Uganda	0.19 (0.12-0.30)		0.41 (0.23-0.75)	
Zambia	0.32 (0.18-0.57)		0.42 (0.21-0.83)	
Having diabetes		0.39		
No	1.00			
Yes	1.37 (0.69-2.74)			
Having high cholesterol level		0.97		
Yes	1.00			
No	0.99 (0.58-1.69)			
Having hypertension		<0.0001		<0.0001
No	1.00		1.00	
Yes	11.14 (8.34-14.86)		7.10 (5.15-9.78)	
High salt intake		<0.0001		
No	1.00			
Yes	0.57 (0.42-0.76)			
Low fruit uptake		0.005		0.07
No	1.00		1.00	
Yes	0.65 (0.49-0.87)		0.78 (0.54-1.13)	
Low vegetable uptake		<0.0001		0.004
No	1.00		1.00	
Yes	0.44 (0.34-0.58)		0.58 (0.54-0.83)	
Physical activity level		<0.0001		0.001
Low Level	1.00		1.00	

Moderate level	0.59 (0.42-0.86)		0.69 (0.45-1.06)	
High level	0.28 (0.21-0.39)		0.74 (0.50-1.10)	
Smoking history		0.008		
Current	1.00			
Never	1.09 (0.70-1.72)			
Previous	2.15 (1.21-3.80)			
Harmful alcohol use		0.40		
No	1.00			
Yes	0.71 (0.31-1.62)			
BMI		<0.0001		<0.0001
<18.5	1.00		1.00	
18.5-24	0.82 (0.51-1.34)		0.77 (0.42-1.39)	
25-29	2.56 (1.55-4.24)		1.06 (0.57-1.93)	
30+	4.30 (2.59-7.13)		1.58 (0.86-2.89)	

[a]P-value from analysis of variance test for an empty model vs a model with a single variable

[b]P-value from analysis of variance where the final model was compared to the model without the corresponding variable

492 Figure 1: Flow diagram of individuals included and excluded in the analysis



493

494

495